Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy for prevention of recurrent infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA) administered by colonoscopy for prevention of recurrent infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial

Background: Recurrent Clostridioides difficile infection (rCDI) occurs in up to 35% of patients with CDI, and further recurrence is common. Fecal microbiota, live-jslm (RBL) is safe and effective for preventing rCDI in adults following antibiotic treatment for rCDI when administered rectally. There...

Full description

Saved in:
Bibliographic Details
Main Authors: Sahil Khanna, David Yoho, Daniel Van Handel, Brian J. Clark, Tahany Awad, Beth Guthmueller, Daniel Armandi, Whitfield Knapple, Nasia Safdar, Brian Baggott, Karen Simon, Paul Feuerstadt
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251339697
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562848251339697

Similar Items